Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis

被引:32
|
作者
Broy, Susan B. [1 ]
Tanner, S. Bobo [2 ]
机构
[1] Chicago Med Sch, Rosalind Franklin Sch Med, N Chicago, IL USA
[2] Vanderbilt Univ, Med Ctr, Div Rheumatol & Allergy, Nashville, TN USA
基金
英国医学研究理事会;
关键词
Rheumatoid arthritis; osteoporosis; osteoporotic fracture; vertebral fracture; fracture risk; FRAX; BONE-MINERAL DENSITY; VERTEBRAL DEFORMITIES; RISK-FACTORS; FRACTURE RISK; INFLAMMATORY MARKERS; JAPANESE WOMEN; HIP-FRACTURES; OSTEOPOROSIS; ASSOCIATIONS; VARIABLES;
D O I
10.1016/j.jocd.2011.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis is the only secondary cause of osteoporosis that is considered independent of bone density in the FRAX (R) algorithm. Although input for rheumatoid arthritis in FRAX (R) is a dichotomous variable, intuitively, one would expect that more severe or active disease would be associated with a greater risk for fracture. We reviewed the literature to determine if specific disease parameters or medication use could be used to better characterize fracture risk in individuals with rheumatoid arthritis. Although many studies document a correlation between various parameters of disease activity or severity and decreased bone density, fewer have associated these variables with fracture risk. We reviewed these studies in detail and concluded that disability measures such as HAQ (Health Assessment Questionnaire) and functional class do correlate with clinical fractures but not morphometric vertebral fractures. One large study found a strong correlation with duration of disease and fracture risk but additional studies are needed to confirm this. There was little evidence to correlate other measures of disease such as DAS (disease activity score), VAS (visual analogue scale), acute phase reactants, use of non-glucocorticoid medications and increased fracture risk. We concluded that FRAX (R) calculations may underestimate fracture probability in patients with impaired functional status from rheumatoid arthritis but that this could not be quantified at this time. At this time, other disease measures cannot be used for fracture prediction. However only a few, mostly small studies addressed other disease parameters and further research is needed. Additional questions for future research are suggested.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [31] High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study
    Gomez-Vaquero, Carmen
    Hernandez, Jose Luis
    Olmos, Jose Manuel
    Cerda, Dacia
    Calleja, Cristina Hidalgo
    Lopez, Juan Antonio Martinez
    Arboleya, Luis
    Rey, Francisco Javier Aguilar del
    Pardo, Silvia Martinez
    Vilamajo, Inmaculada Ros
    Armangue, Xavier Suris
    Grados, Dolors
    Audera, Chesus Beltran
    Suero-Rosario, Evelyn
    Gracia, Inmaculada Gomez
    Chamizo, Asuncion Salmoral
    Martin-Esteve, Irene
    Florez, Helena
    Naranjo, Antonio
    Castaneda, Santos
    Bruno, Soledad Ojeda
    Carazo, Sara Garcia
    Garcia-Vadillo, Alberto
    Vives, Laura Lopez
    Martinez-Ferrert, Angels
    Panos, Helena Borrell
    Acin, Pilar Aguado
    Castellanos-Moreira, Raul
    Satorra, Pau
    Tebe, Cristian
    Guanabens, Nuria
    BONE, 2023, 168
  • [32] Establishment of a preliminary FRAX®-based intervention threshold for rheumatoid arthritis-associated fragility fracture: a 3-year longitudinal, observational, cohort study
    Yu, Shan-Fu
    Chen, Ming-Han
    Chen, Jia-Feng
    Wang, Yu-Wei
    Chen, Ying-Chou
    Hsu, Chung-Yuan
    Lai, Han-Ming
    Chiu, Wen-Chan
    Ko, Chi-Hua
    He, Hsiao-Ru
    Cheng, Tien-Tsai
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [33] Osteoporosis and Rheumatoid Arthritis-Diagnosis, Diagnostics and Therapy
    Buehring, Bjoern
    Thomasius, Friederike
    Schultz, Katharina
    Maus, Uwe
    OSTEOLOGIE, 2021, 30 (04) : 326 - 334
  • [34] Decision making for osteoporotic treatment using FRAX or DVO risk algorithms in a clinical setting
    Rendl, S.
    Lapa, C.
    Bluemel, C.
    Bundschuh, R. A.
    Schneider, P.
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2013, 13 (03) : 339 - 345
  • [35] Clinical observations of osteoporosis in Japanese patients with rheumatoid arthritis
    Furuya, Takefumi
    MODERN RHEUMATOLOGY, 2022, 32 (05) : 839 - 845
  • [36] The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis
    Ratanapha Phuan-udom
    Nittaya Lektrakul
    Wanruchada Katchamart
    Clinical Rheumatology, 2018, 37 : 2603 - 2610
  • [37] Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part I
    Engelke, Klaus
    Lang, Thomas
    Khosla, Sundeep
    Qin, Ling
    Zysset, Philippe
    Leslie, William D.
    Shepherd, John A.
    Schousboe, John T.
    JOURNAL OF CLINICAL DENSITOMETRY, 2015, 18 (03) : 338 - 358
  • [38] Measurement of Foot Bone Mineral Density in Rheumatoid Arthritis: Its Application and Clinical Relevance
    Kamanli, Ayhan
    Suluhan, Ozlem
    Ozgocmen, Salih
    Kaya, Arzu
    Ciftci, Ismail
    Ardicoglu, Ozge
    TURKISH JOURNAL OF RHEUMATOLOGY, 2010, 25 (02) : 56 - 62
  • [39] The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches
    Gupta, Nikhil
    Kanwar, Navjot
    Arora, Anchal
    Khatri, Kavin
    Kanwal, Abhinav
    CLINICAL RHEUMATOLOGY, 2024, 43 (05) : 1421 - 1433
  • [40] Risk factors for treatment failure in osteoporotic patients with rheumatoid arthritis
    Wen, Lihui
    Kang, Ji-Hyoun
    Yim, Yi-Rang
    Lee, Jeong-Won
    Lee, Kyung-Eun
    Park, Dong-Jin
    Kim, Tae-Jong
    Park, Yong-Wook
    Lee, Shin-Seok
    MODERN RHEUMATOLOGY, 2016, 26 (02) : 194 - 199